Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer: methodological comment:

G. Daniele; M. Di Maio; M.C. Piccirillo

Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer: methodological comment

Authors

G. Daniele Clinical Trials Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Napoli, Italy.
M. Di Maio Clinical Trials Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Napoli, Italy.
M.C. Piccirillo Clinical Trials Unit, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, Napoli, Italy.

Abstract

No abstract available

Downloads

Published

2014-04-15

How to Cite

Daniele G, Di Maio M, Piccirillo M. Independent radiologic review of the Gynecologic Oncology Group Study 0218, a phase III trial of bevacizumab in the primary treatment of advanced epithelial ovarian, primary peritoneal, or fallopian tube cancer: methodological comment: . CBN [Internet]. 2014 Apr. 15 [cited 2024 Nov. 23];2(1):35-7. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/264

Download Citation

Issue

Vol. 2 No. 1 (2014): April 2014

Section

Methodological corner

License

Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.